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Abstract
Neurological disorders are medically complex diseases that affect the central and peripheral 
nervous systems. They can affect an entire neurological pathway or a single neuron. Some neu-
rological problems can present years after a causative event. The World Health Organization 
reports that various types of neurological disorders affect millions of people around the 
world. So far, there are no therapies available to cure these disorders. Pharmacological and 
non-pharmacological interventions can at best relieve symptoms and perhaps delay the pro-
gression of the disease. However, there are a wide variety of helpful treatments for different 
disorders that may help an individual to learn better social skills and communication cues, 
in order to help them be able to interact socially, in a more natural fashion. For some neu-
rological issues, the outlook can be quite good with treatment and adequate rehabilitation. 
Diet also plays an important role in the prevention of late-life cognitive decline. Deficits in 
cognition, low dietary quality and physical functioning, and cardio-metabolic risk factors are 
frequently reported in patients with neurological disorders. In this chapter we will briefly 
discuss research, as well as current opportunities and future prospects towards personalized 
medicine in relation to selected neurological disorders and diseases such as Down syndrome, 
neuronal ceroid lipofuscinoses (NCLs), and multiple sclerosis (MS).
Keywords: neurological disorders, free radicals, antioxidants, personalized medicine
1. Introduction
Genes are responsible for forming all of the neurons. However, they are certainly not 
the only factor determining how our brain develops and forms its inner connections. A 
combination of hereditary factors and environmental factors plays an important role in 
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determining a neuron’s final location [1]. Studies confirm that an active lifestyle maintains 
brain function [2]; thus, new research aims to develop lifestyle behaviors and medications 
that could improve normal brain development as well as repair damaged brains. Many neu-
rological disorders emerge during the early years of development and may be diagnosed at 
birth or later, and their causes include congenital, chromosomal, and gene abnormalities, 
infections, immune disorders, and environmental factors such as nutritional deficiencies 
and toxins. The effectiveness of self-management interventions for people with long-term 
neurological conditions, in particular, Down syndrome (DS), neuronal ceroid lipofuscino-
sis (NCL), Duchenne muscular dystrophy (DMD), and multiple sclerosis (MS), has been 
reported. The effectiveness of various antioxidants on several neurodegenerative diseases 
in clinical trials has increasingly demonstrated that reactive oxygen species (ROS) and 
oxidative damage are important factors in the processes involved. Imbalanced defense 
mechanism of antioxidants and overproduction of free radicals from environment to living 
system lead to serious penalty resulting in neurodegeneration [3]. The current need for bet-
ter interventions is highlighted, particularly the importance of providing condition-specific 
information. As the overall life expectancy across the globe has increased, the global com-
munity is now facing new challenges of improving quality of life and healthcare; however, 
advancements in medical technology have benefits and improved healthcare [4, 5]. This 
chapter provides an overview of the evidence of current findings; research limitations and 
future directions of research efforts are discussed in some neurological conditions such as 
DS, DMD, NCL, and MS.
2. Free radicals in the brain
Unlike many other tissues, the brain is a highly aerobic and totally oxygen-dependent tissue. 
Oxygen reduction produces reactive radical intermediates, such as superoxide and hydroxyl 
radicals which are thought to be the major agents of oxygen toxicity [6, 7]. Hydrogen peroxide 
is formed through dismutation of superoxide anion catalyzed by Cu-Zn and Mn forms of 
superoxide dismutase (SOD), both found in the central nervous system. In addition to Cu-Zn 
SOD (SOD-1), the activity of which is increased in DS, and hydrogen peroxide (H
2
O
2
) is gener-
ated in association with D- and L-amino acid oxidase, monoamine oxidase, α-hydroxyacid 
oxidase, xanthine oxidase, and cytochrome P-450 system.
Unlike charged oxygen radicals, H
2
O
2
, being rather unreactive and stable, rapidly crosses cell 
membranes. Cellular damage is accomplished when H
2
O
2
 decomposes to the highly reactive 
hydroxyl radical in reactions catalyzed by iron (II) or copper (I). If the scavenging of H
2
O
2
 
and the contemporaneous prevention of hydroxyl radical formation do not take place, the 
hydroxyl radical may attack, e.g., fatty acid side chains, and start a chain reaction of lipid 
peroxidation. Lipid peroxidation causes gradual loss of membrane fluidity and membrane 
potential and increases membrane permeability to ions [6, 7]. Abnormalities in the fatty acid 
composition found in fetal DS brain phospholipids suggest that from the early stage of onto-
genesis, lipoperoxidation may have a pathological significance [8, 9]. Oxidative degradation 
and polymerization of lipids lead to the accumulation of lipofuscin, the age pigment. Current 
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evidence permits the interpretation that a high proportion of DS subjects later develop the 
neuropathological changes resembling Alzheimer’s disease [10–12].
Considerable evidence has emerged in recent years implicating a role for oxygen free radi-
cals in the initiation of cellular injury that leads to the development of several neurological 
disorders. The neonatal brain, with its high concentrations of unsaturated fatty acids (lipid 
content), high rate of oxygen consumption, and low concentrations of antioxidants, is particu-
larly vulnerable to oxidative damage. Thus, increased oxidative stress has been implicated in 
various neurological disorders such as seizures, ischemia-reperfusion injury, and neurode-
generative diseases [13] such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis 
(ALS, Lou Gehrig’s disease). Free radical damage has been implicated in the initiation and 
propagation of seizure activity as well as the accompanying seizure-induced neuronal dam-
age [14]. Therefore, antioxidants could play an important role in modulating susceptibility to 
seizure activity and seizure-induced neuronal injury.
Radical attack may also destroy membrane-bound enzymes and receptors, e.g., the binding 
of serotonin is decreased. However, the brain tends to need radical reactions for the gen-
eration of physiological responses. Cellular redox adjustments generally regulate functional 
sulfhydryl groups of proteins. There is evidence supporting the suggestion that free radical 
intermediates are involved, e.g., in the coupling between depolarization of the plasma mem-
brane Ca2+ fluxes and neurotransmitter release [15, 16]. It has also been hypothesized that 
the elimination of neurofilaments at nerve terminals is regulated by oxygen radicals and 
that a contact of a growing neurite with a neighboring neuron induces the production of 
oxygen radicals. Rapid elimination of oxygen radicals during synaptogenesis would result 
in a reduced number of synaptic connections [17]. Accordingly, transgenic mice bearing the 
human SOD gene develop abnormalities in neuromuscular junctions of the tongue which 
closely resemble those of DS patients [18]. However, these abnormalities may be explained by 
a decreased level of superoxide anion as well as by increased formation of highly active and 
toxic hydroxyl radicals and singlet oxygen.
The regulation of glutathione (GSH) level (GSH/GSSG) through pentose phosphate pathway 
producing nicotinamide adenine dinucleotide phosphate (NADPH), GSH reductase, and glu-
tathione peroxidase (GSHPx) contributes to the overall redox state of cells in brain [19]. The 
brain tends to need radical reactions as well as to possess specific or high endogenous levels 
of free radical scavengers such as dopamine, norepinephrine, catechol estrogens, taurine, and 
carnosine [20] in neurons. Carnosine is involved with GABA activity in the brain, and brain 
tissue contains high levels of carnosine, which is capable of reducing the oxidative, nitrosa-
tive, and glycemic stress to which the brain is especially vulnerable [21–23]. Oxidation and 
glycation produce inflammation and also contribute to cross-linking of proteins, including 
the Alzheimer’s disease protein called amyloid-beta [24]. A study by Takahashi [25] demon-
strated that homocarnosine levels were high in patients who responded to antileptic drugs. 
The functional balance between various free radical scavenger systems in the brain seems 
reasonable. Significant positive correlations between catalase and SOD levels have been 
reported in tissues of normal subjects excluding erythrocytes. Factors concomitantly influenc-
ing the variation of the activities of SOD, catalase, and GSHPx have been reported. Enzymes 
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frequently called protective should rather be envisaged as being regulatory, controlling the 
levels of different states of oxygen reduction, phorbol esters, and strong superoxide produc-
ers through NADPH oxidase activation [26–29], inducing biosynthesis of polyamines [30, 31]. 
The role of polyamines is also associated with the architectural modeling of brain regions and 
generation of synaptic connections [32–34]. Thus effective scavenging of superoxide by excess 
SOD-1 may contribute even to the polyamine biosynthesis.
In addition to the complex enzyme systems, biochemical defenses include low molecular weight 
free radical scavengers and antioxidants. Lipid soluble vitamin E lowers the steady-state con-
centrations of many free radical species [35–39]. Ubiquinone may exert, similarly to vitamin E, 
a protective effect against lipid peroxidation [40]. The concentration of vitamin E in a fetal DS 
brain does not significantly differ from that of controls [41]. We have found the serum vitamin E 
concentrations of Down syndrome patients to be normal (1.01 + 0.35 vs. 1.13 + 0.39 mg/100 ml) 
[42]. In addition to conventional antioxidant systems, the brain has been found to contain specific 
or high endogenous levels of free radical scavengers such as dopamine, norepinephrine [43–45], 
catechol estrogens [20], carnosine [46], and taurine [47, 48]. The transport of taurine to platelets 
is impaired in DS [49]. Taurine and hypotaurine, found in high concentrations in the brain [50], 
could act as intracellular superoxide scavengers which would inhibit not only lipid peroxidation 
but also inactivation of SOD by both superoxide and H
2
O
2
 [51, 52]. The presence of 1–10 mM 
taurine protects cultured lymphoblastoid cells from the injurious effect of iron-ascorbate [48].
The role of dietary beta-carotene in the central nervous system is not elucidated. Beta-
carotene acts as an antioxidant at low oxygen pressures [53–55]. Being converted to retinol or 
retinoic acid, it causes a marked decrease in superoxide generation. Through a still unknown 
mechanism, retinoic acid induces human neuroblastoma cell differentiation in vitro [56–58], 
and it also contributes to neural differentiation of embryonal  carcinoma cells in vitro [59].
Serum β-carotene and vitamin A levels are generally normal in DS, although vitamin A levels 
lower than in normal subjects have also been reported. Relatively high carotene/vitamin A 
ratio suggests decreased efficiency in converting carotene to vitamin A. In addition the utili-
zation of vitamin A in DS may be impaired at its site of action [60–62].
Thyroid hormones improve the cleaving of beta-carotene to vitamin A. This conversion to 
retinol is decreased in hypothyroidism. Thus, in hypothyroidism the vitamin A concentration 
decreases even when the dietary β-carotene remains the same or rises [63, 64].
3. Down syndrome
Down syndrome (DS), also known as trisomy 21, is a genetic disorder caused by the presence 
of all or part of a third copy of chromosome 21 [65]. It is one of the most common chromosome 
abnormalities in humans [66]. Globally, as of 2010, DS occurs in about 1 per 1000 births [67] 
and results in about 17,000 deaths [68].
In spite of the intensified antenatal diagnostics and termination of affected pregnancies, the 
prevalence of DS, first described in 1866, is still so high that it constitutes an important health-
care problem. DS phenotype is readily recognized at birth. Karyotype analysis confirms the 
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diagnosis of DS associated with trisomy of chromosome 21. Since the further development 
of the child is predestined to be hampered by a multitude of clinical symptoms including 
mental retardation, premature aging, and immunological disorders such as hypothyroid 
states, attempts have been made to increase the understanding of the etiopathogenesis of the 
syndrome and to influence its progress.
The genetic imbalance due to an extra set of normal genes located in chromosome 21 means 
that the expression of these or actually of only some genes in the q arm leads to the disturbed 
development. Cumulative effects of increased amounts of primary gene products may be 
deleterious if no compensatory mechanisms exist. Genes of the q arm in chromosome 21, 
which may contribute to the DS pathology, include α/β interferon receptor, phosphoribosyl-
glycinamide synthetase [69–72], cystathionine beta synthase [73], and cytoplasmic Cu-Zn 
superoxide dismutase (SOD-1) [74, 75].
DS, described in a karyotypically normal 18-month-old boy, has been explained by a micro-
duplication of a chromosome 21 fragment (not exceeding 2000–3000 kilobase pairs) contain-
ing the SOD-1 gene [76, 77]. Further evidence of the involvement of additional SOD-1 gene 
in the neuropathological symptoms of DS has been derived from studies performed with 
transgenic cell lines and from mice carrying the human SOD gene [18, 78].
Consistent with the gene dosage effect, SOD-1 activity is increased in the cerebral cortex of DS 
fetuses as well as in erythrocytes, blood platelets, leukocytes, and fibroblasts of DS patients [79] 
(Thilakavathy et al. 2008). According to Sinet [75], elevated SOD-1 activity may constitute an 
oxygen free radical “stress.” Usually SOD-1 protects cells from the harmful effects of oxygen 
radicals by catalyzing formation of H
2
O
2
 from O
2
− enzymes that remove excessive peroxides 
like catalase and glutathione peroxidase (GSHPx) [74]. NADPH is needed for the regeneration 
by glutathione reductase of glutathione (GSH), the utilization of which is increased via GSHPx 
as a defense against peroxide formation. Thus several enzymes with structural loci other than 
those of chromosome 21, including glutathione reductase, glutathione peroxidase, and glucose-
6-phosphate dehydrogenase, show elevated activity in erythrocytes of DS patients [80, 81].
Some reports suggest that Both SOD GSHPx activities are increased in Down syndrome chil-
dren [82]. It remains to be seen whether oxidative damage will still be related to the accumu-
lation of aluminum silicates in the brain as well as to that of the senile plaques and tangles. 
Experiments have indicated that aluminum salts may not only accelerate Fe (II)-induced 
peroxidation of membrane lipids but do this especially in the brain [83]. Interestingly a high 
proportion of Down syndrome patients develop the neuropathological and clinical changes of 
AD suggesting a close pathogenetic relationship between these disorders. Thus the correction 
of antioxidant balance in AD by Se supplementation should be demonstrated by other means 
so as to direct it preventatively to those with a high risk of developing AD.
Balazs and Brooksbank [8] noticed that the adaptive response to elevated SOD-1 activity, 
i.e., increased GSHPx activity found in other tissues, is not detected in the fetal DS brain. 
The level of GSHPx activity in neural tissues seems to be as such too low to provide protec-
tion from peroxide-induced lesions [84]. Furthermore, if H
2
O
2
 production is high, catalase 
might be a superior scavenger, because restoration of glutathione becomes a limiting factor 
for the activity of GSHPx [85]. However, catalase level is normal in DS erythrocytes [72, 86], 
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and its activity is practically absent in the brain tissue [87]. Consequently brain cells may be 
extremely susceptible to oxygen free radicals.
3.1. The pathophysiology of Down syndrome and the role of the thyroid gland
Thyroid hormone has a regulatory function on mitosis and differentiation of neural cells; 
hence, it is intimately involved in normal brain maturation [88–91]. Experimentally trijodo-
thyronine enhances neural outgrowth in vitro [92, 94]. Even subclinical hypothyreosis during 
the postnatal period may contribute to the delayed and incomplete maturation of the cerebral 
and cerebellar cortices.
Increased prevalence of thyroid dysfunction is associated with DS in infants as well as in 
older children and adults [95–98]. Hypothyroidism is reported in 17–50% of the DS patients 
studied depending on the age and sex distribution of the population [98]. The relatively high 
incidence of autoimmune thyroiditis suggests that impaired immune surveillance is the 
primary mechanism in hypothyroidism [99]. Pueschel and Pezullo [98] conducted a study 
which showed that approximately 28% of their 151 DS patients had elevated antimicrosomal 
antibodies, and a highly significant correlation of antimicrosomal antibodies to T4 and to 
TSH was found. Recent studies indicate that antimicrosomal antibodies are mainly, if not 
exclusively, against thyroid peroxidase [100].
Thyroid peroxidase is a membrane-bound enzyme associated with the endoplasmic reticu-
lum and the apical membrane of the thyroid cell. lmmunoelectron microscopical observations 
of the thyroid microsomal antigen in the apical plasma membrane are compatible with the 
notion that microsomal antigen is identical with thyroid peroxidase [101–104].
SOD-1 system, which generates H
2
O
2
, is essential in the iodination and coupling reactions 
catalyzed by thyroid peroxidase [105–107]. However, an excess of H
2
O
2
 may inactivate the 
peroxidase complex [105–108]. The irreversible loss of catalytic activity, caused by H
2
O
2
 or by 
the reactive oxygen species generated, may result from oxidation of functionally important 
amino acid residues to carbonyl derivatives. This may also render the protein susceptible to 
proteolytic attack and to detachment of its cellular compartment. If so, the maintenance of the 
thyroid peroxidase function and its integrity would require correct steady-state production of 
H
2
O
2
 and strict control of its level. This requirement is mainly met with by GSHPx and catalase.
Antigenicity of the modified and disintegrated thyroid peroxidase should be recognized by 
helper lymphocytes only in the context of MHC Class 11 products coded by genes in the 
HLA-D region. This region normally expressed only by a restricted variety of cell types is 
found in autoimmune disorders in target cells. Thus an aberrant expression of HLA-DR anti-
gen found on thyrocytes in Graves’ and Hashimoto’s disease indicates its potential impor-
tance in antigen presentation of thyroid autoimmune disorders [109, 110].
The presence and intensity of DR expression in Graves’ thyroids correlate positively with 
the titer of microsomal antibodies. Curiously, in cultured thyroid cells, plant lectins are 
able to induce the expression of HLA-DR by a mechanism unrelated to the known mito-
genic effects. On the other hand, the inducing effect of gamma-interferon (IFN-γ) could 
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have a physiological significance (IFN-α and IFN-β did not induce Class II expression in 
thyrocytes) [111–113]:
• Release of IFNs and lymphokines, best candidates for inducers, must be triggered by other 
factors [111–113].
On the basis of the gene dosage effect, we suggest possible mechanisms for the sensitization 
of DS thyroids to autoimmunization:
• Viral challenge including enhanced production of oxygen radicals due to macrophage and 
neutrophil activity may exert additional requirement for GSHPx and selenium. If these 
needs are not met with overproduction of oxygen radicals and constitutive excess of both 
LFA-1 and its beta-chain, it may hinder normal immune response [111–114].
• Excess H
2
O
2
 causes fragmentation of thyroid peroxidase which detaches from the cell 
membrane and turns into an autoantigen.
• Increased expression of IFN-α/IFN-P receptors, the gene of which is found in chromosome 
21, may sensitize thyrocytes to the induction of HLA-DR antigen by γ-IFN [111–113].
3.2. The impact of early hearing loss on language
Down syndrome occurs in approximately 1 in 600–800 live births [115] and remains the most 
common genetic abnormality seen in most otolaryngology practices. Down syndrome has 
a number of clinical problems associated with it [116–118]. The symptoms of DS vary from 
person to person, and people with the syndrome may have different problems at different 
times of their lives [119]. Hearing loss will affect many people with Down syndrome at some 
point in their lives. It has been reported that children with Down syndrome are at particular 
risk of some degree of hearing impairment due to a number of physiological differences. The 
authors concluded that there are a range of middle ear problems that can be treated success-
fully if the children are taken for routine cleaning and examination from birth [120]. Hearing 
losses affect 40–80% of individuals with DS [121–124]. In young children, the most common 
cause is conductive loss due to episodes of ear infection and otitis media with effusion (OME).
To determine the prevalence of hearing loss in newborn with Down syndrome, Tedeschi 
et al. [125] reported that newborn with Down syndrome have a higher prevalence of con-
genital hearing loss than the total neonatal population (15 vs. 0.25%). Individuals with Down 
syndrome are prone to otolaryngologic anomalies that complicate the diagnosis and classifi-
cation of hearing impairment [126]. In children, hearing loss can affect educational, language-
related, and emotional development. Even mild hearing loss can affect a child’s articulation. 
It is reported that as many as 80% of people with Down syndrome will have some problem 
with hearing [127]. A retrospective and cross-sectional analysis was performed to evaluate the 
prevalence of OME in children with DS for consecutive age categories between 6 months and 
12 years [128]. The authors concluded that a high prevalence of OME was found at the age of 
1 year (66.7%), with a second peak prevalence of 60% at 6–7 years. A declining trend was seen 
in older children [128].
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As with children, adults with DS may experience hearing loss due to glue ear. Picciotti et al. 
[129] assessed auditory function in adults with DS to evaluate the prevalence of hearing loss. 
The authors concluded that hearing loss is common in adults with DS and shows a pattern 
compatible with precocious aging of the hearing system.
3.3. Hearing and spoken language
Disorders impairing a patient’s communication abilities may involve voice, speech, language, 
hearing, and/or cognition [130]. The effect of hearing difficulties on spoken language develop-
ment has been demonstrated in many studies of the speech and language skills of children 
and teenagers with Down syndrome [131, 132].
Most individuals with DS also experience speech and language impairments although the 
severity of these is variable [133, 134]. Researchers studying language development in DS 
have measured hearing either directly tested or using pure tone audiometry to establish hear-
ing thresholds [135] or, indirectly, using speech discrimination tasks [136–138]. Therefore, it 
suggested that speech and language therapy should be provided when children are found to 
have ongoing hearing difficulties and that joint audiology and speech and language therapy 
clinics could be considered for preschool children [138].
4. Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is one of the most severe myopathies, usually obvi-
ous by the age of 5, and evolves progressively until it causes disablement and death, around 
the age of 20 [139]. In young boys, DMD is caused by deletions or point mutations in the 
pre-mRNA for dystrophin that result in out-of-frame transcripts and hence a nonfunctional 
truncated dystrophin protein [140]. It is recessively inherited, linked to sex, and the gene 
determining DMD has been mapped in the Xp-21 locus [141]. It has an incidence of 1/3000–
1/3500 male births and 1/3 of the cases coming from new mutation. Some affected individuals 
may develop intellectual disturbance due to unknown mechanism, so far. The sister of an 
affected individual has a 50% chance of carrying the defective gene [141]. The result of the 
dystrophic locus on the gene is the absence of dystrophin, a rod-shaped protein that is part of 
the muscle cytoskeleton. Death commonly results from involvement of the respiratory mus-
cles. Dystrophin is present in the muscle of normal individuals and has been rarely, or not at 
all, detected in patients with DMD [142, 143]. The genetic alteration produces abnormality in 
the membrane of the muscular fibers that consists of a disturbance in the calcium transport 
(Ca2+), inside the muscular fibers, which is the base mechanism of cellular degeneration and 
necrosis. There is fiber necrosis and replacement of fibers by fat. A nucleotide degradation 
and decreased muscle ATP and ADP content have been reported. The ATP is necessary to 
drive the Na+/K+ pump which maintains ionic gradients across the sarcolemma; resequester 
the Ca++ into the cisternae; and power contraction [144–146]. The production of ATP can be 
the result of anaerobic respiration, which breaks glucose down into ATP and lactic acid, or 
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aerobic respiration when ATP, carbon dioxide, and water are formed. A second immediate 
reserve of energy exists in the form of creatine phosphate, which can donate phosphate to 
ADP to form ATP, becoming itself a creatine. In the resting muscle, glucose is stored as gly-
cogen, and in such a muscle aerobic respiration synthesizes ATP from glucose or fatty acids.
Muscle dystrophy and mitochondrial dysfunction give rise to an amplification of stress-
induced cytosolic calcium signals and an amplification of stress-induced reactive oxygen 
species (ROS) production, and increased oxidative stress within the cell damages the sar-
colemma and eventually results in the death of the cell. Muscle fibers undergo necrosis and 
are ultimately replaced with adipose and connective tissue. In recent years, synthetic splice-
switching oligonucleotides (SSO) have been developed as new treatments for DMD whereby 
an SSO is targeted to the pre-mRNA and mediates splicing redirection to restore the reading 
frame of the dystrophin gene via exon skipping and thus to generate a shorter but functional 
dystrophin protein isoform [140, 147–155]. Several SSO chemistries have been developed for 
exon skipping in DMD and other neuromuscular diseases [156, 157], but of these only two 
SSO chemical types have been used in clinical trials, namely, 2′-O-methyl phosphorothioates 
(2′-OMe/PS) [158] and phosphorodiamidate morpholino oligonucleotides (PMO) [159, 160].
Therapy of DMD has been an elusive goal. Studies with isolated myocytes have shown that 
lipid peroxidation with an enhanced free radical production can be activated by increasing 
Ca concentration [161–163]. Thus, several kinds of antioxidants have been proposed as a treat-
ment since increased levels of thiobarbituric acid (TBA) reactive material has been found in 
the muscles and blood of DMD males [164]. We have previously reported that the biological 
half-life of 75Se in DMD patients was significantly shorter than in healthy controls [165]. Low 
oxygen saturation in the muscle tissue may stimulate the Il-6 production, a cytokine, which 
is produced by contracting muscles and released into the blood. The blood circulation of the 
older Duchenne patients is particularly disturbed. Pedersen et al. [166] have demonstrated 
that Il-6 affects the metabolic genes, induction of lipolysis, inhibition of insulin resistance, 
and stimulation of cortisol production. In addition, carbohydrate supplementation during 
exercise was shown to inhibit the release of Il-6 from contracting muscles. Thus carnitine 
supplementation is indicated to the Duchenne patients, to make sure that the energy supply 
will be good [167].
Shimomura et al. [168] observed that a group of trained animals, part of which were coen-
zyme Q10 (CoQ10)-treated, had to exercise for 30 min on treadmill, in downhill position. CoQ10-treated animals had a higher level of CoQ10 in their muscles, and the early rise in creatine kinase and lactic dehydrogenase plasma levels, due to the exercise, was evident 
at a remarkably significant lower extent, in the treated ones. Similar observations were 
also made in humans [169, 170]. Therefore we have been treating the Duchenne patients 
with CoQ10. In our earlier work, we gave DMD patients sodium selenite, 0.05–0.1 mg Se kg−1 BW day−1; α-tocopherol, 10–20 mg kg−1 BW day−1; vitamin B
2
, 0.2 mg kg−1 BW day−1; 
vitamin B
6
, 5 mg kg−1 BW day−1; carnitine, 10–20 mg kg−1 BW day−1; and ubiquinone-10 (CoQ10), 3 mg kg−1 BW day−1 [171]. We reported two siblings of whom the elder one got practically no antioxidants and the younger one has antioxidant treatment starting at the 
age of 6 years. The first one was wheelchair bound at the age of 8 years and deceased at 
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the age of 17 years. However, at the age of 15 years, the younger brother was still able to 
walk without any assistance. At the age 19 years, he was to be a graduate student with the 
best scores of all seven subjects that he participated. At the age of 21 years, he was still 
able to swim a distance of 50 m without any assistance. At age of 30 years, he is still able 
to make computer art and to have art exhibitions of his own. There are also mothers who 
have made observations that the odor of lard characteristic of their DMD sons was cured 
during the antioxidant supplementation. Potential future developments therapy may be 
to produce functional amounts of dystrophin by skipping the mutated exon like what has 
been done in mdx dystrophic mouse [172–174].
5. Neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinoses (NCLs) are clinically heterogeneous neurodegenerative lyso-
somal diseases [175–179]. NCLs are recessively inherited neurodegenerative lysosomal stor-
age diseases. The neuronal ceroid lipofuscinoses are with a prevalence of 1 in 12,500 in some 
populations such as the USA and Northern Europe. Currently the classification is based on 
genetic defects, with 14 clinical subtypes and genetically separate neurodegenerative disor-
ders that result from excessive accumulation of lipopigments (lipofuscin) in the body’s tis-
sues, and the most prevalent NCLs are CLN3 disease, classic juvenile and CLN2 disease, and 
classic late infantile [39, 176, 180–182]. Characteristics of the diseases are deposits of ceroid 
and lipofuscin pigments in the tissues, particularly in the neural tissue, visual failure, and 
progressive mental retardation; depending on the age of onset and clinical, electrophysiologi-
cal, and neuropathological features, the NCLs can be subdivided into the infantile the late 
infantile, the juvenile and the adult type of NCL; however, the pathogenesis of NCL is still 
unknown.
5.1. Management of neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinoses are a group of hereditary diseases caused by mutations 
in at least eight genes (CLN1-CLN8) [183, 184]. They are characterized by massive accu-
mulation of autofluorescent lysosomal storage bodies in most cells and associated severe 
degeneration of the CNS [183]. There is no single, standard treatment for neuronal ceroid 
lipofuscinoses (NCLs), as there is currently no cure; however, a number of different treat-
ments can be used to ease symptoms and encourage independence and better standards 
of general health [185]. Also there are certain medical problems that can affect someone 
with neuronal ceroid lipofuscinosis. However, a number of different treatments can be 
used to ease the symptoms and encourage independence and better standards of general 
health. These treatments are based on each individual’s physical and intellectual needs 
as well as their personal strengths and limitations: enzyme replacement therapy, gene 
therapy, stem cells including tissue engineering, and medicine or metabolic therapy such 
as dietary restriction and immune biotherapy [186–190]. These modes of treatments have 
been used in many genetic diseases. Acetyl-L-carnitine (ALC) has been shown to be thera-
peutic in treatment of NCLs [191]. It was reported that ALC might rebalance the disorders 
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underlying neuronal ceroid lipofuscinosis disease which are related to a disturbance in pH 
homeostasis [191].
The polyenic acid level with low levels of linoleic acid and an inverse relationship between 
GSHPx activity and the level of eicosatrienoic acid have been observed in juvenile neu-
ronal ceroid lipofuscinosis (JNCL) [192]. The occurrence of the fluorescent pigments 
suggested the peroxidation of lipids in the etiology of NCL. It is likely that the diseased 
tissues peroxidized cause secondary damage more rapidly than normal tissues and cyto-
toxic end products of lipoperoxidation. On a weight basis, ceroid seen in JNCL patients 
binds five times more iron than the lipofuscin seen in normal elderly individuals. The 
increased levels of aluminum salts greatly enhance iron-dependent damage to membranes. 
Heiskala et al. [193] has confirmed the presence of complexable iron and copper in the CSF 
of patients with NCL and other neurological disorders, and when the pH value of the assay 
for iron was lowered, the NCL group had substantially more complexable iron in their 
CSFs. Interestingly aluminum has been observed in CSF and in ceroid lipofuscin pigments 
of the brain of NCL patients [194]. It is well established that damaged tissue release metals 
from protein-bound sites and these metals stimulate peroxidative damage to lipids and 
other biomolecules.
One of the most essential enzymes counteracting lipoperoxidation is the selenium-containing 
GSHPx. Two independent reports have demonstrated that erythrocyte GSHPx activity is 
decreased in JNCL patients [195]. This low GSHPx activity was reversed to normal level by 
selenium supplementation. The evaluation of sodium selenite absorption and losses before 
supplementation of JNCL patients has been studied by using total body counting for 75Se 
detection. These studies showed that in three JNCL patients, about 55% of the administered 
75Se was eliminated during the first 11 days in the feces and about 10% in the urine [39]. 
Compared to healthy controls (42 and 7%, respectively), findings indicate a reduced absorp-
tion of selenium in JNCL patients contrary to a previous report. The low GSHPx activity in 
NCL patients may indeed reflect a low selenium intake most probably due to a disturbed 
absorption of selenium and secondary phenomena due to an inborn error of metabolism. 
Apart from the low selenium status, also very low vitamin E levels are found in the serum 
of advanced and hospitalized NCL patients. This can be explained by the recent finding of a 
pronounced reduction of apolipoprotein B as well as the whole fraction of very low-density 
lipoprotein (VLDL) in JNCL patients.
JNCL patients (genetically subgroups) have been given daily supplementation of sodium 
selenite (0.05–0.1 mg/Se/kg of BW), vitamin E (α-tocopherol acetate 0.014–0.05 g/kg BW), and 
vitamins B
2
 (0.025–0.05 mg/kg BW) and B
6
 (0.63–0.8 mg/kg BW). The benefits of the therapy 
are corroborated by the significant negative correlation of GSHPx activity with neurological 
dysfunction of motor performance, balance, coordination, and speech [196]. The mean age at 
death has been extended by 4 years as compared to that at the beginning of the century. As the 
best responders to antioxidant therapy show no neurological dysfunction at the age of over 
20 years, there is no doubt that the life expectancy of JNCL patients receiving antioxidants, 
including selenium, will be significantly prolonged in the future [197]. Complications of the 
antioxidant therapy have been few and not severe. Six patients have experienced vomiting and 
Personalized Management of Selected Neurological Disorders
http://dx.doi.org/10.5772/intechopen.92002
133
nausea when the serum concentration of selenium reached the level of 0.45 to 0.5 mM. Serum 
levels up to 4.0 mM were usually well tolerated, as well as when the sodium selenite was 
changed to ebselen (2-phenyl-1,2,-benzisoselenazol-3(2H)-one).
6. Multiple sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, 
where suspected autoimmune attack causes nerve demyelination and progressive neuro-
degeneration and should benefit from both anti-inflammatory and neuroprotective strate-
gies [198]. MS affects an estimated 4.3 cases per 100,000 in Europe with a higher rate in 
Northern Europe [199]. Often it appears in individuals between 20 and 40 years of age and 
has a strong genetic component [200]. The disease course is benign in 10–15% of patients, 
and they do not need an assistive device for walking even after 20 years of MS [201, 202]. 
Low levels of polyenic acids are involved in the pathogenesis of both MS and JNCL. Earlier 
a decrease level of serum linoleate as well as unsaturated fatty acids of brain phospholipids 
in MS patients was shown [203, 204]. It has also been argued that supplementation with 
essential fatty acids may improve the clinical status of MS patients [205]. And as in NCL, 
the selenium may, by activating GSHPx (scavenger of organic peroxides), regulate the 
metabolic transformation of essential fatty acids and biotransformation of these to pros-
taglandins, thromboxanes, and leukotrienes [206]. Curiously decreased GSHPx activities 
in erythrocytes have been found in female but not in male MS patients [207]. A significant 
association between the two haplotypes of the dopamine D2 receptor gene (DRD2) and the 
age of onset and/or diagnosis of MS was reported [208].
Current treatments for MS mainly target inflammatory processes, and there has been scant 
progress in treatments that enhance neuronal or glial regeneration. Can we predict the risk 
of serious side effects? This asks for the development of biomarkers, clinical, genetic, imag-
ing, or immunological, that allow for a better stratification of patients [209]. The need for 
tailored therapeutics is especially imperative, as the consequences of an ineffective medica-
tion might be irreversible dysfunction. However, it is obvious that treatment decisions in 
clinical practice must be made on an individual basis. This requires a personalized medicine 
approach in predicting disease activity in multiple sclerosis. Biomarkers that could predict 
disease course, treatment response, and risk of side effects would be highly appreciated. 
Despite extensive research over the last years, few biomarkers have made their way into 
clinical practice.
7. Advances in the development of novel antioxidant therapies
Earlier, through intervention efforts, patients with DS have received medical treatment and 
stimulation of sensory, motor, and cognitive areas [210]. In 1981, Harrell et al. [211] reported that 
the administration of a megavitamin mineral supplement to a heterogenous group of 16 men-
tally retarded children, 4 of which had DS, had led to encouraging results. However, controlled 
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double-blind studies on somewhat larger groups using similar megadoses of vitamins and miner-
als but no thyroid supplementation did not result in any beneficial effects [212–216]. However, 
these studies were devoid of a detailed theory of the mechanism of action, and the age distribution 
of the patients was disadvantageous in relation to possible targets in the developing brains.
Our primary survey and theory of antioxidant therapy in DS [42, 217] rest on the present 
concepts of the etiopathogenesis of DS [8, 79]. Earlier, selected antioxidants have been used, 
e.g., in the therapy of neuronal ceroid lipofuscinosis [218]. Prevention of free radical damage 
should be executed by agents focused on the tissue and cellular compartments and processes 
where the generation of free radicals is critical. In DS, elevated cytoplasmic SOD-1 activity 
causes free radical stress through H
2
O
2
. An excess of H
2
O
2
 may be activated in iron- or copper-
catalyzed reactions to generate highly reactive hydroxyl radical (–OH) or singlet oxygen. The 
extent and nature of the damage depend on the precise site of the •OH production, which in 
turn depends on the intra- or extracellular location of the critical metal ions [7, 219].
However, GSHPx, which gives protection against elevated H
2
O
2
, is low in brains with intensive 
oxygen metabolism. Histochemical studies by Slivka and co-workers [220] are indicative of 
the relative absence of GSH in neuronal somata and locate GSH to non-neuronal elements 
and fibrous and terminal regions of neurons. Furthermore, in normal newborn infants, the 
activity of GSHPx is physiologically low [221, 222]. Just a reflection of this condition could be 
the low blood selenium level found in neonates [223]. Controversial results have been pub-
lished on the level of selenium in plasma and erythrocytes of DS patients [79]. Peripherally 
decreased GSHPx activity may be corrected by selenium supplementation [224, 225]. Unlike 
catalase, benefit of optimal GSHPx activity is gained through its capability to reduce both H
2
O
2
 
and organic hydroperoxides including lipid peroxides. The mean plasma selenium concentra-
tion in DS patients has been shown not to differ significantly from that of the control subjects 
although the GSHPx activity is 130% of the normal [226]. Neve and co-workers [227] reported 
normal erythrocyte but significantly decreased plasma selenium levels in 29 DS patients. These 
discrepancies may be explained by the differences in the population groups studied and by 
the distribution of the blood selenium pool. Only 10–15% of the erythrocyte selenium in man 
is reported to be incorporated into the GSHPx, whereas the corresponding value in rat is 
75–85% [228].
We noticed in DS patients of different ages that the mean compensatory increase of erythro-
cyte GSHPx was lower than expected, 33.4 vs. 50%. The finding that the erythrocyte SOD/
GSHPx ratio was higher than in healthy controls confirmed our belief of insufficient com-
pensation [42, 217]. In DS the whole body retention of 5–8 kBq, 75Se-sodium selenite, with 
0.4 ug Se as carrier/kg BW, is estimated to be 53.3 ± 21.1%. Stable selenium supplementation 
increased 75Se elimination indicating a saturated selenium pool in the body [229]. Selenium 
supplementation 0.025 mg Se/kg/d in the form of sodium selenite increased E-GSHPx activ-
ity by 28 (59.9% above normal). This was also demonstrated by the 23.9% decrease of SOD/
GSHPx ratio (P < 0.01) [42, 217].
The consequences of selenium supplementation on the brain antioxidant balance, and thus 
its therapeutic value, are difficult to monitor. However, certain clinical, experimental, and 
in vitro observations may be indicative [230]. A highly positive correlation has been reported 
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between erythrocyte GSHPx values and IQ in DS [231]. The plasma selenium concentration 
and erythrocyte GSHPx activity were found to be higher in DS girls than in DS boys, which 
is consistent with the finding of significantly higher IQ scores for female than for male DS 
patients. The positive correlation of E-GSHPx activity between DS subjects and their siblings 
suggests the influence of environmental and/or additional genetic factors [26, 230].
Estimates of the amount of selenium in the rat brain indicate that the GSHPx may account for 
only ⅕ of the total selenium in the brain [232]. The finding that selenoproteins other than GSHPx 
are distributed mainly in the brain and endocrine organs raises a question of their physiologi-
cal role. After the administration of very small amounts of selenium, severely depleted rats 
retained in the brain and in the reproductive and several endocrine organs (including thyroid) 
a dose which was 20–50 times the dose found in adequately fed control animals. This indicates 
the existence of regulatory mechanisms which ensure a sufficient level of selenium in critical 
organs, above all in the brain and the thyroid even during depletion [91, 233].
In concentrations of 6 x 10-7 M, selenite induces a 30-fold increase of GSHPx activity in neu-
roblast cells in vitro [234]. Earlier studies on the rat liver suggested that selenium regulates 
the level of GSHPx mRNA as well as GSHPx protein concentration and GSHPx activity [235]. 
Concentrations of 10-5 M exert obvious toxic effects on nerve fibers in vitro [236]. Trace elements, 
as “doping impurities” in organic material, could be key variables that regulate conductivity 
in biological semiconduction structures [237]. We suggest that the abnormally high levels of 
copper and iron and the low level of zinc ion in erythrocytes and blood mononuclear cells are 
reflections of disturbed oxygen radical metabolism in DS. However, increased concentration 
of copper can be explained as gene dosage evident by the increased activity of SOD-1 [238]. 
Except for the decreased iron content in erythrocytes, the results were in accordance with an 
earlier study [239]. Ferrous-ion (Fe II) and copper-ion (Cu I) react with H
2
O
2
 producing •OH 
radicals [240, 241]. Titanium in erythrocytes may indicate insufficient protection by GSHPx. If 
titanium is present as Ti (IV), stable compounds may be formed with hydrogen peroxides and 
probably with superoxide anions to give 1:1 adducts [238]. The low plasma zinc concentration 
in DS children has been recognized in earlier studies as well [242, 243]. The homeostasis of 
zinc is regulated by the intestine. The absorption of zinc seems to be decreased in DS, mean 
retention of zinc being 30% compared with 58% in healthy adults. Stable zinc supplementa-
tion in one DS patient did not increase the 65Zn elimination, indicating an unsaturated zinc 
pool [229].
Interestingly, the primarily high blood mononuclear cell levels of copper decreased, whereas 
the concentration of iron and zinc was not affected during selenium supplementation [244]. 
No significant alterations were observed in the erythrocyte concentrations of magnesium, 
calcium, iron, copper, zinc, sulfur, titanium, and manganese. Aluminum was not found in 
erythrocytes nor in neutrophils of DS patients [238].
8. Brain antioxidant homeostasis in relation to selenium and GSHPx
In nature the availability of selenium, as a trace element, may be limited. GSHPx activity 
has been shown to reflect selenium status in deficient and adequate states [245]. On the 
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other hand, protection against toxicity is likely to involve the alterations in GSH metabo-
lism that occur in nutritional Se deficiency. A high concentration of erythrocyte glutathione 
in patients with neurological disorders has been reported [246–248]. However, regulatory 
mechanisms apparently exist which ensure that during periods of insufficient selenium 
intake, the content of the element is kept up above all in the brain and the reproductive and 
the endocrine organs.
Selenium seems to be somehow involved in the regulation of oxygen metabolism through its 
influence on a variety of enzymes. In concentrations of 6 × 10−7 to ×10−6 M, selenite induces a 
30-fold increase of GSHPx activity in neuroblast cells in vitro. Other studies with the rat liver 
have suggested that Se status regulates the level of GSHPx mRNA as well as GSHPx protein 
concentration and GSHPx activity [235]. In concentrations of 0.7 − 2 × 10−5 M, Se in the rat liver 
increases the activities of γ-glutamylcysteine synthetase, the first rate-limiting enzyme in GSH 
biosynthesis, and GSSG reductase, which catalyzes the reduction of GSSG to GSH [249]. In some 
species the induction of GSH S-transferase has been shown to occur as a result of Se deficiency. 
Hydrogen peroxide as the most stable and diffusible of the oxygen reduction intermediates may 
exert an influence on the expression of SOD, catalase, and GSHPx activities. The homeostasis 
in the oxidative metabolism and oxygen reduction may be distorted by different means either 
inherent or acquired. Depending on the spatial and temporal occurrence of the distortion, vari-
ous neurological states are expressed. The developing brain is particularly susceptible to oxida-
tive stress more so than the mature brain [250]. H
2
O
2
 accumulation has also been associated 
with increased injury in the superoxide dismutase-overexpressing neonatal murine brain, and 
greater cell death is seen when immature neurons are exposed to H
2
O
2
 than with mature neu-
rons. Increased H
2
O
2
 accumulation may be the result of relative insufficiency of the endogenous 
enzyme GSHPx.
Under physiologic circumstances, the brain has efficient antioxidant defense mechanisms, 
including GSHPx, which converts potentially harmful H
2
O
2
 to oxygen and water at the 
expense of reduced GSH. Under oxidative stress, in the immature brain, endogenous levels 
of GSHPx may be inadequate for converting excess H
2
O
2
. Transgenic mice that overexpress 
GSHPx (hGPx-tg), when subjected to hypoxia-ischemia (HI), have less histologic brain injury 
than their WT littermates [19]. In addition, the cortex exhibits increased GSHPx enzyme activ-
ity at 24 h, whereas GSHPx activity remains unaltered in the WT brain. In addition, neu-
rons cultured from the hGPx-tg brain are resistant to injury from exogenously applied H
2
O
2
 
[251]. Neurons cultured from the hippocampus and cortex that are transfected (transfection 
describes the introduction of foreign material into eukaryotic cells) with genes for catalase 
and GSHPx also show protection from neurotoxic insults and a corresponding decrease in 
H
2
O
2
 accumulation [252]. These findings indicate that adequate GSHPx activity can amelio-
rate injury to the immature brain from oxidative stress due to H
2
O
2
.
It is well established that a previous stress to the brain can induce tolerance to subsequent injury, 
a phenomenon called personality change (PC). In neonatal rodents, protection against HI brain 
injury has been induced by PC with a period of hypoxia before the induction of HI [253]. The 
mechanisms of this protection have yet to be fully determined, but it has been established that a 
large number of genes are induced in response to hypoxia [254]. Many of these genes are regu-
lated by the transcription factor hypoxia-inducible factor-1α (HIF-1α), perhaps most importantly 
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vascular endothelial growth factor (VEGF) and erythropoietin (EPO). VEGF is upregulated after 
focal ischemic injury in the neonatal rat, in parallel with the induction of HIF-1α [255].
9. Current opportunities and future prospects towards personalized 
medicine
Neurological disorders are diseases that affect the central and peripheral nervous systems. 
They can affect an entire neurological pathway or a single neuron; the neurodegeneration 
describes the loss of neuronal structure and function [256]. They are caused by genetic muta-
tions present during embryo or fetal development, although they may be observed later 
in life [257–259]. The mutations may be inherited from a parent’s genome, or they may be 
acquired in utero. The risk factors for the diseases are diverse, including age, genetics, life-
style, etc. Inflammatory conditions represent a major causative factor in numerous medically 
significant disorders. It can result from a range of stimuli from outside or within the body. 
However, these stimuli trigger cells and physiological processes within a host environment. 
It is believed that environmental exposures increase the risk of developing the disease. Even 
in inherited cases, exposure to toxins or other environmental factors may influence when 
symptoms of the disease appear or how the disease progresses [258, 260, 261].
With an increase in life span and decrease in death rate, the prevalence of these chronic recur-
ring condition are rising all over the world. Moreover, no direct therapy/treatment is avail-
able now, which can reverse or retard the pathophysiological processes permanently. The 
medication (drug) regimen needs to be well integrated with healthy diet and lifestyle to attain 
high-quality and longer lives [262]. Therefore, the complex physiopathological mechanisms 
must now be clarified, and the immunological and genetical causes to neurological diseases 
must be investigated. New research on gene changes linked and gene therapy to neurological 
disorders is helping scientists better understand the disease, in which DNA or RNA is used 
as the pharmacological agent, defined as gene therapy [263]. Both genetic and environmental 
factors are known to influence susceptibility to diseases. Therefore, environmental factors 
may also have a protective effect.
The role of free radicals is well established in etiopathogenesis of neurological disorders. Some 
of the known antioxidants, which can prevent oxidation chronic recurring condition, have 
been studied [38, 39]. Recent developments in basic research have confirmed the relationship 
between etiopathogenesis and supplementation therapy with vitamins and trace elements. 
Supplementation therapy studies should be conducted. We need more clinical experience 
and a longer follow-up period with our neurological disorder patients receiving antioxidant 
therapy to reach more final conclusions concerning efficacy in the control of optimal develop-
ment. Studies are now looking at the possible effects of these compounds more closely to 
develop related compounds that are even more potent and might be used as dietary supple-
ments. However, so far, most research suggests that a balanced diet is of greater benefit than 
taking these substances as dietary supplements.
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10. Personalized medicine approaches
Neurological diseases cannot be managed by using one single approach. These disorders, 
like all chronic diseases, are a complex metabolic system that is related to the way a patient’s 
genes interact with their individual environment. Therefore, precise and reliable testing 
methods are needed including patient biomarkers, age, and genetic history. Oxidative stress 
has been linked to dozens of chronic conditions [264, 265]. Identifying the cause of oxidative 
stress such as emotional stressors, poor diet, smoking, metal toxicity [266], chemical exposure, 
and pesticides can be of help [266, 267]. To balance free radicals may require lifestyle and diet 
modifications such as antioxidant supplementation [268, 269].
There is no doubt that the nervous system is involved in the etiopathogenesis of various 
pathological states and diseases. Interactions between the nervous, endocrine, and immune 
systems might represent the anatomical and functional basis for understanding the pathways 
and mechanisms that enable the brain to modulate the progression of disease. For example, 
an increasing number of pharmacogenetic association studies in DS are being reported [270, 
273]. Personalized medicine is an evidence-based, individualized medicine that delivers the 
right care to the right patient at the right time and results in measurable improvements in out-
comes and a reduction on healthcare costs. However, in order to make personalized medicine 
effective, genomic techniques must be standardized and integrated into health systems and 
clinical workflow. Though personalizing drug treatment on the basis of individual genotype 
rather than ethnicity may be more appropriate, differences in allele frequencies across conti-
nents should be considered when designing clinical trials of new drugs [270]. For example, 
new therapies for treating DS require quality of life measurement, such as the use of stem 
cells in order to develop treatments which may improve the intelligence of those affected with 
the syndrome [274]. Other methods being studied include the use of antioxidants, gamma 
secretase inhibition, adrenergic agonists, and memantine [275–279].
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